1. Medtech Insight
  2. >>Leadership

MedLumics Names VC Veteran James Greene CEO

 
• By Reed Miller

MedLumics appointed James Greene as its CEO and Giovanni Leo to the board of directors. The Madrid-based company expects the two industry veterans to carry it through the its next phase of growth – commercialization of the AblaView AF catheter.

MedLumics SL has named James Greene, a partner with Dublin venture capital firm Seroba Lifesciences, as its new CEO. Greene takes over the CEO job from MedLumics’ founder, Eduardo Margallo, who will stay with the company as its chief operating officer.

Greene's task will be to lead the Madrid-based company in commercializing its AblaView optically guided, radiofrequency atrial fibrillation catheter. AblaView integrates "optical coherence reflectometry," a proprietary multibeam technology, into the...

More from Leadership

More from Medtech Insight

TRiCares Tricuspid Valve Replacement System Reduces Regurgitation In First-In-Human Study

 
• By Natasha Barrow

TRiCares presented data from the first-in-human study for its tricuspid valve replacement system – Topaz – at EuroPCR 2025 on 22 May.

Swiss Medtechs Advised To Work On US Tariff Mitigation Strategies

 
• By Ashley Yeo

The US’ 90-day suspension of higher “reciprocal tariffs” will expire on 9 July, raising fears that the 31% tariff rate on Swiss medtech and other goods exported to the US might make a comeback. While the tariff situation changes on an almost daily basis, medtechs should forearm for any eventually, say local business organizations.

Guardant Health Launches Germline Hereditary Cancer Test

 
• By Natasha Barrow

Guardant Health introduces a new germline panel test to help guide cancer treatment, assess the risk of secondary cancers in patients and identify family members at risk of cancer.